

SPINE SAFETY CAUTIONARY NOTICE:

Information for Healthcare Professionals: Drug Safety Labeling Changes - DepoDur (morphine sulfate extended-release) liposome injection

According to MedWatch, FDA notified healthcare professionals that PRECAUTIONS text for DepoDur have been updated to address dosing issues. The revised PRECAUTIONS indicates the following:

PRECAUTIONS

General

- revised to include statement to reinforce that DepoDur dosing will need to be adjusted in the elderly and other risk groups taking into account the patient's age, body mass, physical status, prior experience with opiate analgesics, risk factors for respiratory depression, and medications to be co-administered before or during surgery

CLINICAL PHARMACOLOGY

Drug Interactions

- revised to include pharmacokinetic interaction with respect to DepoDur and therapeutic doses of local anesthetic bupivacaine HCl

Read the complete summary of MedWatch safety labeling changes at:

<http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm186886.htm>

The North American Spine Society is committed to quality patient care through promotion of patient safety and prevention of medical errors. NASS monitors a variety of government and other resources for patient safety related notices that may be useful to our members. Information from these notices is also archived on the NASS website at <http://www.spine.org/Pages/PracticePolicy/ClinicalCare/SpineSafetyAlerts/Default.aspx>. This information is provided as a service for information and education only.